Description
Orfoxen 9 Mg contains orforglipron, an oral medicine that belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist class. Everest Pharmaceuticals lists Orfoxen 9 as an export product containing orforglipron 9 mg.
Orforglipron is a newer medicine developed for metabolic conditions. In April 2026, the U.S. Food and Drug Administration approved the orforglipron brand Foundayo for long-term weight management in certain adults with obesity or overweight and a weight-related medical condition.
The product name Orfoxen should not automatically be treated as the same product as Foundayo. Manufacturer, registration, approved uses, formulation, and availability must be checked for the specific product being supplied.
This page provides general medicine information. It does not replace a prescription, diagnosis, or advice from a qualified prescriber or pharmacist.
The manufacturer and product details above are based on the supplied product brief and the manufacturer’s public product listing. Confirm the actual packaging, registration, and prescribing information before publication.
Key Benefits and Medical Uses
Orforglipron activates GLP-1 receptors. This action affects appetite, food intake, and blood glucose regulation. It is being developed and used in the treatment of metabolic conditions.
The FDA-approved Foundayo label identifies long-term weight management as an approved use in certain adults with obesity or overweight and at least one weight-related medical condition. It is used with a reduced-calorie diet and increased physical activity.
Do not assume that every Orfoxen product has the same approved uses as Foundayo. The approved indication for Orfoxen 9 Mg must be confirmed using the applicable local product information.
Active Ingredient
The active ingredient is orforglipron. Official prescribing information for Foundayo identifies orforglipron as a non-peptide GLP-1 receptor agonist.
The exact salt form, excipients, and formulation for Orfoxen 9 Mg should be confirmed from the manufacturer’s product insert.
How Orforglipron Works
Orforglipron acts on GLP-1 receptors. GLP-1 is a hormone involved in appetite regulation and blood glucose control.
In simple terms, GLP-1 receptor activity can:
- Influence appetite and food intake.
- Help regulate blood glucose.
- Slow the movement of food from the stomach into the intestine.
The official label notes that Foundayo delays gastric emptying and may affect the absorption of other oral medicines.
This medicine is not a replacement for a balanced diet, physical activity, or professional medical care.
Indications and Approved Uses
The FDA-approved Foundayo product is indicated with diet and increased physical activity for long-term weight management in certain adults with obesity or overweight and a weight-related comorbid condition.
Orforglipron has also been studied for type 2 diabetes and other metabolic conditions. Research activity does not mean that a product is approved for every condition.
Before using Orfoxen 9 Mg, confirm:
- The approved indication in your country.
- Whether the product is intended for your condition.
- Whether a qualified prescriber has recommended it.
- Whether the product’s registration and label are valid.
Dosage and Administration
Do not use this page to choose your dose. The correct dose depends on the specific product label, indication, medical history, and prescriber’s instructions.
The official Foundayo label states that it is taken orally once daily, with or without food. Tablets should be swallowed whole and not broken, crushed, or chewed.
Orfoxen 9 Mg may not have identical dosing instructions. The applicable product insert must be checked before any administration advice is published.
Missed Dose
The official Foundayo medication guide states that a missed dose should be taken as soon as possible without doubling the next dose. If seven or more consecutive doses are missed, the label instructs patients to restart dose escalation at a lower dosage.
Follow the instructions for your actual product and ask a pharmacist if you are unsure.
Available Strengths
Everest Pharmaceuticals’ public product listing includes Orfoxen in several strengths:
- 0.8 mg
- 2.5 mg
- 5.5 mg
- 9 mg
- 14.5 mg
- 17.2 mg
The listing identifies these as export products.
The availability of these strengths does not mean that all are approved or available in every country.
Available Pack Sizes
The pack size for Orfoxen 9 Mg must be confirmed from the actual manufacturer packaging or official product documentation.
Do not publish “30 tablets,” “one-month supply,” or any other pack size unless it has been verified.
How to Take Orfoxen 9 Mg
Use Orfoxen 9 Mg only as directed by a qualified prescriber.
Before taking the medicine:
- Read the supplied product information.
- Confirm the strength and product name.
- Follow the prescribed schedule.
- Tell your prescriber about other medicines.
- Ask about any food, drink, or medicine restrictions.
- Do not change the dose without professional guidance.
The official Foundayo label contains specific administration and missed-dose instructions. Those instructions should not automatically be copied to a different product without verification.
Who Can Use This Medicine?
Orforglipron may be prescribed to eligible adults for an approved indication. Eligibility depends on medical assessment, local approval, and the actual product label.
A prescriber may consider:
- The patient’s medical history.
- The reason for treatment.
- Current medicines.
- Previous treatment response.
- Kidney and liver function.
- Pregnancy status where relevant.
- Potential contraindications.
Age restrictions and approved indications must be confirmed for the country where the product will be used.
Who Should Not Use It?
The official Foundayo label lists important contraindications.
Patients with a personal or family history of medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia syndrome type 2 (MEN 2), should not use Foundayo. A serious allergy to orforglipron or its ingredients is also a contraindication.
These restrictions must be reviewed by a qualified prescriber for the specific Orfoxen product.
Warnings and Precautions
Orforglipron requires medical supervision.
Thyroid Tumor Warning
The official Foundayo label contains a boxed warning about the risk of thyroid C-cell tumors. Animal studies observed tumors with certain GLP-1 medicines, and the human relevance of this finding remains undetermined.
Pregnancy
The official label states that Foundayo may cause fetal harm and should be discontinued when pregnancy is recognized.
Oral Contraceptives
The official label advises people using oral hormonal contraceptives to use a non-oral method or add a barrier method for 30 days after starting treatment and 30 days after each dose escalation.
Other Medical Conditions
Discuss the medicine with a prescriber if you have a history of:
- Thyroid cancer.
- Pancreatitis.
- Severe gastrointestinal disease.
- Gallbladder disease.
- Kidney problems.
- Liver problems.
- Severe allergies.
- Conditions affecting food or medicine absorption.
The official label should be checked for the complete warning list.
Possible Side Effects
The official Foundayo medication guide lists common adverse effects including nausea, diarrhea, constipation, vomiting, and decreased appetite.
Other possible reactions may occur. Not every patient experiences the same effects.
Seek urgent medical attention for serious symptoms such as severe allergic reactions, breathing difficulty, or other symptoms that concern you.
Do not stop or change treatment without speaking to a qualified prescriber, unless urgent medical care is needed.
Drug Interactions
Orforglipron may affect the absorption of oral medicines because it delays gastric emptying. The official label specifically warns that this can affect concomitantly administered oral medications.
Tell your prescriber about:
- Diabetes medicines.
- Oral contraceptives.
- Medicines with a narrow therapeutic index.
- Prescription medicines.
- Over-the-counter medicines.
- Vitamins and supplements.
A pharmacist can help identify possible interactions before treatment begins.
Storage Instructions
Storage requirements must be confirmed from the Orfoxen 9 Mg package insert.
Keep the medicine in its original packaging and follow the manufacturer’s instructions. Keep it out of reach of children.
Do not use tablets that appear damaged, altered, or improperly stored.
Conclusion
Orfoxen 9 Mg (Orforglipron) is an oral GLP-1 receptor agonist product listed by Everest Pharmaceuticals. Orforglipron is a newer medicine with regulatory approvals that vary by product and country.
Before using Orfoxen 9 Mg, confirm the product’s approved indication, manufacturer information, prescription requirements, and safety guidance.
For questions about the product, contact a qualified pharmacist or prescriber. Use official product information to support safe and informed decisions.
Reviews
There are no reviews yet.